Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Alings

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
European Heart Journal|September 2, 2024
Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trialsRenate B Schnabel, Juan Benezet-Mazuecos, Nina Becher, et al.
Lancet (London, England)|November 15, 2017
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trialSonia S Anand, Jackie Bosch, John W Eikelboom, et al.
The New England Journal of Medicine|November 12, 2023
Apixaban for Stroke Prevention in Subclinical Atrial FibrillationJeff S Healey, Renato D Lopes, Christopher B Granger, et al.
The New England Journal of Medicine|September 1, 2020
Colchicine in Patients with Chronic Coronary DiseaseStefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd, et al.
BMJ Open|August 27, 2020
Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillationGordon Chu, Jaap Seelig, Emmy M Trinks-Roerdink, et al.
The New England Journal of Medicine|August 7, 2020
Subcutaneous or Transvenous Defibrillator TherapyReinoud E Knops, Louise R A Olde Nordkamp, Peter-Paul H M Delnoy, et al.
Gastroenterology|June 2, 2019
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or AspirinPaul Moayyedi, John W Eikelboom, Jackie Bosch, et al.
Gastroenterology|May 6, 2019
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled TrialPaul Moayyedi, John W Eikelboom, Jackie Bosch, et al.
The New England Journal of Medicine|August 29, 2017
Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseJohn W Eikelboom, Stuart J Connolly, Jackie Bosch, et al.
Circulation|April 25, 2025
Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL TrialLouise R A Olde Nordkamp, Jolien A de Veld, Abdul Ghani, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
European Heart Journal|September 2, 2024
Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trialsRenate B Schnabel, Juan Benezet-Mazuecos, Nina Becher, et al.
Lancet (London, England)|November 15, 2017
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trialSonia S Anand, Jackie Bosch, John W Eikelboom, et al.
The New England Journal of Medicine|November 12, 2023
Apixaban for Stroke Prevention in Subclinical Atrial FibrillationJeff S Healey, Renato D Lopes, Christopher B Granger, et al.
The New England Journal of Medicine|September 1, 2020
Colchicine in Patients with Chronic Coronary DiseaseStefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd, et al.
BMJ Open|August 27, 2020
Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillationGordon Chu, Jaap Seelig, Emmy M Trinks-Roerdink, et al.
The New England Journal of Medicine|August 7, 2020
Subcutaneous or Transvenous Defibrillator TherapyReinoud E Knops, Louise R A Olde Nordkamp, Peter-Paul H M Delnoy, et al.
Gastroenterology|June 2, 2019
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or AspirinPaul Moayyedi, John W Eikelboom, Jackie Bosch, et al.
Gastroenterology|May 6, 2019
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled TrialPaul Moayyedi, John W Eikelboom, Jackie Bosch, et al.
The New England Journal of Medicine|August 29, 2017
Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseJohn W Eikelboom, Stuart J Connolly, Jackie Bosch, et al.
Circulation|April 25, 2025
Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL TrialLouise R A Olde Nordkamp, Jolien A de Veld, Abdul Ghani, et al.
Pageof 13